Argenx
Argenx
ARGX
EURONEXT
539.80
EUR
-5.00%
About
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications.
It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 45.1K |
| Three Month Average Volume | 1.4M |
| High Low | |
| Fifty-Two Week High | 493.6 EUR |
| Fifty-Two Week Low | 271 EUR |
| Fifty-Two Week High Date | 20 Sep 2023 |
| Fifty-Two Week Low Date | 20 Dec 2023 |
| Price and Volume | |
| Current Price | 468.1 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.35% |
| Thirteen Week Relative Price Change | 28.65% |
| Twenty-Six Week Relative Price Change | 15.16% |
| Fifty-Two Week Relative Price Change | -11.77% |
| Year-to-Date Relative Price Change | 20.75% |
| Price Change | |
| One Day Price Change | -1.27% |
| Thirteen Week Price Change | 37.39% |
| Twenty-Six Week Price Change | 30.28% |
| Five Day Price Change | 0.75% |
| Fifty-Two Week Price Change | 0.71% |
| Year-to-Date Price Change | 36.27% |
| Month-to-Date Price Change | -0.64% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 62.66031 EUR |
| Book Value Per Share (Most Recent Quarter) | 64.52361 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | 60.74529 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | 62.37738 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.41419 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 19.41753 EUR |
| Revenue Per Share (Trailing Twelve Months) | 24.82707 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | 0 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.67188 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.14979 EUR |
| Normalized (Last Fiscal Year) | -4.67188 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.67188 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.14979 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -4.67188 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -3.14979 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 48.62713 EUR |
| Cash Per Share (Most Recent Quarter) | 46.96458 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -2.90944 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -109 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -14.48% |
| Pretax Margin (Last Fiscal Year) | -24.83% |
| Pretax Margin (5 Year) | -98.26% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 90.39% |
| Gross Margin (Trailing Twelve Months) | 89.41% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -34.66% |
| Operating Margin (Trailing Twelve Months) | -22.17% |
| Operating Margin (5 Year) | -96.30% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -24.06% |
| Net Profit Margin (Trailing Twelve Months) | -12.65% |
| Net Profit Margin (5 Year) | -97.72% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 32.17% |
| Tangible Book Value (5 Year) | 45.11% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 76.54% |
| Revenue Growth (3 Year) | 117.25% |
| Revenue Change (Trailing Twelve Months) | 101.45% |
| Revenue Per Share Growth | 95.14% |
| Revenue Growth (5 Year) | 209.80% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 122.32% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 128.85% |
| EPS Change (Trailing Twelve Months) | 51.41% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 8 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -2,777,565,000 |
| Net Debt (Last Fiscal Year) | -2,860,354,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 25 |
| Price to Sales (Trailing Twelve Months) | 19 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | 0.00% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 7 |
| Price to Book (Most Recent Quarter) | 7 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 1 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 9 |
| Quick Ratio (Most Recent Quarter) | 8 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 10 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -420,147,900 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 1 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -7.69% |
| Return on Assets (Trailing Twelve Months) | -5.11% |
| Return on Assets (5 Year) | -17.65% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -8.54% |
| Return on Equity (Trailing Twelve Months) | -5.74% |
| Return on Equity (5 Year) | -20.86% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -8.49% |
| Return on Investment (Trailing Twelve Months) | -5.70% |
| Return on Investment (5 Year) | -19.79% |